Status:
COMPLETED
BAY63-2521 - Long-term Extension Study in Patients With Chronic Thromboembolic Pulmonary Hypertension
Lead Sponsor:
Bayer
Conditions:
Pulmonary Hypertension
Eligibility:
All Genders
18-80 years
Phase:
PHASE3
Brief Summary
Patients who have completed the 16 weeks treatment of the CHEST-1 trial (study number 11348) will be asked to participate in this long term extension study with BAY63-2521. The aim of the long term st...
Eligibility Criteria
Inclusion
- Patients who have completed 16 weeks of treatment in the double blind trial CHEST 1
Exclusion
- Patients who have an ongoing serious adverse event from CHEST 1 that is assessed as related to BAY63-2521 are not allowed to participate in the extension trial
Key Trial Info
Start Date :
July 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 19 2019
Estimated Enrollment :
237 Patients enrolled
Trial Details
Trial ID
NCT00910429
Start Date
July 1 2009
End Date
August 19 2019
Last Update
November 7 2023
Active Locations (73)
Enter a location and click search to find clinical trials sorted by distance.
1
La Jolla, California, United States, 92093
2
Sacramento, California, United States, 95817
3
Iowa City, Iowa, United States, 52242
4
Baltimore, Maryland, United States, 21205